Elevated levels of SIGLEC-15 correlate with poor prognosis in various malignancies, including lung adenocarcinoma, pancreatic cancer, and colorectal cancer, suggesting its involvement in tumor progression and immunosuppression [10,11]. Here, SIGLEC15 is linked to neoplasm.